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Amyotrophic lateral sclerosis (ALS) is one of the group of diseases of the central nerve 
system (CNS), which are characterized by progressive loss of structure and function of 
neurons in different regions of brain or spinal cord.  Therefore, these diseases are 
collectively designated as “Neurodegenerative Diseases” (NDDs). Usually the loss of 
specific functions precedes the death of affected neurons, and the related clinical features 
depend on localization and degree of neurodegeneration. NDDs include such diseases as 
Alzheimer’s, Parkinson’s, Huntington’s, spinocerebellar ataxias, and ALS. In spite of 
differences in predominant localization of neurodegeneration and clinical features, there are 
many parallels among different neurodegenerative disorders. These include involvement of 
mitochondrial dysfunctions, increased oxidative stress, and atypical protein assemblies 
(Backman et al., 2006). 
Amyotrophic lateral sclerosis (ALS) refers to several adult-onset conditions characterized by 
progressive degeneration of motor neurons. “Amyotrophic” refers to the muscle atrophy, 
weakness, and fasciculation (spontaneous contraction affecting a small number of muscle 
fibers) that signify disease of the lower motor neurons. There are two forms of this fatal 
disease: sporadic, with no known genetic component, and familial, which make up about 
10% of all ALS cases (Rowland & Schneider, 2001; Martin et al., 2009). Among the familial 
cases, approximately 20% are caused by dominantly inherited mutations in the Cu/Zn 
superoxide dismutase (SOD1) gene, with more than 100 known mutations (reviewed in 
Bruijn et al., 2004). So far, there is very little information that links familial and sporadic 
cases of the disease. One established fact, based on studies of patients and transgenic 
animals, is that mitochondria dysfunction is an early manifestation. However, it is unclear 
whether mitochondrial dysfunctions are the primary pathogenic mechanism, or the result of 
some other proximate pathogenic mechanism. 
Although the cases associated with mutations in the SOD1 gene comprise only about 2% 
of all ALS cases, understandably, transgenic animals bearing mutated SOD1 gene 
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became the major targets for research on pathogenesis of ALS (Bendotti and Carri, 2004; 
Bruijn et al., 2004; Matsumoto et al., 2006). Of these, a transgenic mouse carrying the 
G93A (Gly-93  Ala) mutant human SOD1 gene was the first described (Gurney et al., 
1994). This animal model of ALS was used all over the world because it closely 
recapitulates clinical and histopathological features of the human disease (Matsumoto et 
al., 2006).  
Researchers from Wyeth, John Hopkins and Harvard in collaboration with ALS 
Association as part of its Lou Gehrig Challenge Initiative established the SOD1G93A 
mutant rat line. Taconic (Germantown, NY) established a production colony in 2002, 
which was sponsored by grant funding from ALS Association. The original publication 
on this strain (tgSOD1) reported disease onset around 115 days of age, with rapid disease 
progression thereafter (Howland et al., 2002). Taconic has maintained a colony since 
2002. In our recent work (Panov et al., 2011b) we presented data obtained in 2007 on 45 
tgSOD1 animals obtained from 9 separate simultaneous isolations of BM and SCM. We 
studied respiration and reactive oxygen species production by mitochondria isolated 
from the brains (tgBM) and spinal cords (tgSCM), of such rats and the results obtained 
were highly reproducible (Panov et al., 2011b). Beginning late in 2008 and in 2009 we 
encountered difficulties in reproducing the results obtained in 2007. Moreover, we have 
found that the transgenic rat line did not develop symptoms of the disease at age of more 
than 200 days even though the mutated gene was evident in DNA samples from tails and 
ears. In 2010 we received information from Taconic (Germantown, NY) that changes in 
features can be attributed to a variable phenotype in this model, “which may be due to in 
part to both the outbred nature of the background strain as well as to possible copy 
number variation of the transgene” (Information Letter from Taconic). Whether these 
phenotypic changes were associated with the decline of the level to which the transgene 
was expressed is impossible to conclude because, in the rats studied in 2007, neither 
Taconic company, nor our lab quantified the expression of the mutated SOD1 gene or 
protein. Nevertheless, our comparative studies of metabolic properties of BM and SCM 
suggest that potentially the loss of morbidity could be explained by different patterns of 
substrates metabolism and associated ROS generation in BM and SCM studied in 2007 
and 2010.  
In 2008 we found that BM and SCM isolated from the wild type Sprague Dawley rats 
began to show metabolic features that were different from those described earlier for the 
same strain of the wild type and tgSOD1 rats (Panov et al., 2009, 2011a). In this work we 
present a comparison of metabolic phenotypes and the substrate–dependent ROS 
generation in the wild type and transgenic rats with mutant G93A Cu/Zn-superoxide 
dismutase gene isolated in 2007 and 2010. We conclude that the shift in mitochondrial 
metabolic phenotype, which resulted in a dramatic decrease in ROS production by tgBM 
and tgSCM, may have contributed to the significant loss of morbidity of the established 
tgSOD1 rat line. This could result from the breeding method of the transgenic animals, 
when males bearing the dominant mutated SOD1 gene were mated with the wild type 
females. Because mitochondrial DNA has maternal inheritance (Wallace, 2001), the 
resulting progeny has the mitochondrial phenotype of females, and thus the mutated 
SOD1 protein was acting on mitochondria with different metabolism that resulted in 
much lower rates of ROS production. We conclude that mitochondria are the key players 
in the pathogenesis of ALS. 
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We suggest a hypothesis, which links together pathogenic mechanisms of sporadic and 
familial forms of ALS. Our hypothesis is based on results obtained in experiments on 
animals, which showed that between species and even within one species there may exist 
different phenotypes of mitochondrial metabolism. Neuronal mitochondria of some 
phenotypes may produce very large amounts of superoxide radical, which is dismutated 
to hydrogen peroxide (H2O2). High levels of H2O2 may damage the extramitochondrial 
isoform of superoxide dismutase (SOD1). The oxidatively damaged proteins lose Cu and 
Zn from the hem centers, and the demetallated protein enters mitochondrial membranes, 
further increases ROS production by a mechanism similar to that described for 
cholesterol-ǃ-D-glucoside and fitosterol glucosides (Panov et al., 2010b), causes 
mitochondrial dysfunctions, and finally the death of neurons. These are sporadic cases of 
ALS associated with disorders of mitochondrial metabolism. The familial cases with 
mutations in the SOD1 gene have basically the same mechanism of motor neuron death, 
but, because mutated SOD1 protein is exceptionally sensitive to oxidative damage, the 
loss of Cu and Zn may occur at relatively low levels of H2O2 formation by neuronal 
mitochondria. The predominant involvement of spinal cord can be accounted for by 
metabolic and structural features of spinal cord and SCM, which were published 
elsewhere (Panov et al., 2011a, 2011b).  
2. General characterization of mitochondria in ALS 
Clinical features of ALS, a severe neuromuscular degenerative disease, were described by 
Charcot in 1874 (Rowland & Shneider, 2001). Since that time clinical definitions (Shook and 
Pioro, 2009) and pathological features of the disease have been greatly expanded, aided in 
no small measure by advances in genetics of the disease (Rowland & Shneider, 2001) and 
development of transgenic animal models of ALS (Bendotti & Carri, 2004; Matsumoto et al., 
2006; Howland et al., 2002). However, the etiology and pathogenesis of the disease remain 
poorly understood.  
Clinical and experimental evidence showed that ALS is a systemic disease, with 
particular vulnerability of motor neurons due to some unique properties (Martin et al., 
2007; von Lewinski & Keller, 2005; Panov et al., 2011a). Many ALS patients are 
hypermetabolic, an early and persistent phenomenon (Bouteloup et al., 2009, Desport et 
al., 2005). Muscular mitochondrial function in amyotrophic lateral sclerosis is 
progressively altered in ALS patients (Echaniz-Laguna et al., 2006, Krasnianski et al., 
2005), and subtle ultrastructural changes of hepatocytes and liver dysfunction have also 
been described in biopsy specimens from ALS patients (Nakano et al., 1987). Significant 
changes were also found in skeletal muscle mitochondria of transgenic SOD1 (tgSOD1) 
animals (Dupuis et al., 2009, Krasnianski et al., 2005). It was suggested that increased 
ROS generation by skeletal muscle mitochondria (Muller et al., 2007) or mitochondrial 
uncoupling (Dupuis et al., 2009) may be primarily responsible for the loss of 
neuromuscular junctions and secondary distal degeneration of motor neurons in SOD1 
mice. This is an interesting and important alternative hypothesis, which requires a more 
detailed and critical discussion. 
The paper by Muller et al. (2007) presents data on generation of ROS by skeletal muscle 
mitochondria (SMM) from two lines of transgenic mice bearing different mutations in 
SOD1 gene, SOD1 knockout mice, and mice with denervated muscle. The authors 
www.intechopen.com
  
Amyotrophic Lateral Sclerosis 
 
228 
concluded that “enhanced generation of mitochondrial ROS may be a common factor in 
the mechanism underlying denervation-induced atrophy”. The authors suggested also 
that increased ROS generation in ALS mutant model may also cause the loss of neuro-
muscular junctions, and thus initiate the loss of motor neurons. There are, however, 
experimental facts, which oppose this conclusion. Muller et al (2007) isolated skeletal 
muscle mitochondria using a protease nagarse for digestion of the tissue. With the 
nagarse method, more than 90% of mitochondria are interfibrillar. Without the protease 
the yields of subsarcolemmal mitochondria are very low (A. Panov, unpublished 
observations). ROS generated in situ by interfibrillar mitochondria are unlikely to gain 
access to the sarcolemmal membrane where the neuro-muscular junctions are located. 
This is because superoxide radical has difficulty to leave mitochondria (Panov et al. 
2005). Besides, both superoxide radicals and H2O2 are substrates for the antioxidant 
enzymes in the cytoplasm, such as SOD1, catalase, etc. Rather, it is more likely that 
increased ROS act locally to cause damage to interfibrillar mitochondria, particularly to 
mtDNA, and thus cause muscle atrophy. Data presented by Muller et al. (2007) do not 
show direct damage to neuromuscular junctions by increased ROS. Therefore this issue 
requires further study. There is also a quantitative aspect of ROS generation presented 
by Muller et al. (2007). A comparison of the rates of ROS production by skeletal muscle 
mitochondria (SMM) (Figure 1 in Muller et al., 2007) and brain (BM) and spinal cord 
mitochondria (SCM) (see Fig. 7 in Panov et al., 2011a) shows that BM and SCM generate 
several times more ROS than SMM. Therefore, it is more likely that the causes of 
degeneration of motor neurons in ALS are associated with primary pathological 
processes in neurons rather than in muscle.  
Dupuis et al. (2009) also concluded that “a muscle restricted mitochondrial defect is 
sufficient to generate motor neuron degeneration”. The authors based their conclusion on 
mitochondrial dysfunctions observed in animals with overexpression of uncoupling protein 
1 (UCP1). Overexpression of UCP1 results in deenergization of the mitochondria due to 
increased conductivity of the inner membrane for protons. This condition results in 
complete inhibition of ROS production associated with the energy-dependent reverse 
electron transport. The major consequence of overexpression of UCP1 is inhibition of ATP 
production and suppression of functions, which depend on mitochondrial ATP levels. 
Because in neuronal tissue reverse electron transport is the major source of ROS production 
(Panov et al. 2007, 2009), and increased ROS generation is one of the leading pathogenic 
pathways in ALS, the mechanism proposed by Dupius et al. (2009), although interesting, 
probably has little to do with neurodegeneration in ALS. 
It was hypothesized that sporadic and familial forms of ALS may share some final 
pathogenic mechanisms (Bendotti & Carri, 2004; von Lewinski & Keller, 2005). Several 
pathogenic factors have been proposed (reviewed in Bruijn et al., 2004): glutamate 
excitotoxicity (Heath & Shaw, 2002); mitochondrial dysfunction (Dupuis et al., 2009); 
increased production of reactive oxygen species (ROS) (reviewed in Barber & Shaw, 2010) 
and nitroxyradicals (NO- and ONOO-) (Martin et al., 2007); deregulation of Ca2+ homeostasis 
and triggering of permeability transition of mitochondria (von Lewinski and Keller, 2005;  
Martin et al., 2009; Morota et al., 2007); induction of pro-apoptotic pathways (Przedborski, 
2004); misfolding and intracellular accumulation of mutant SOD1 (Tateno et al., 2004), 
including in brain and spinal mitochondria (Liu et al., 2004; Higgins et al., 2002); mutant 
SOD1-induced conformational changes in Bcl-2 (Pedrini et al., 2010) and VDAC1 (porin) 
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(Israelson et al., 2010); and abnormal axonal transport (Magrane & Manfredi, 2009). 
However, almost all of these proposed pathogenic mechanisms directly or indirectly involve 
mitochondria. The major problem in searching for alternative pathogenic mechanisms, in 
case of severe mitochondrial disability, is that practically all cellular and organ functions 
depend on energy and thus also become disturbed (Gershoni et al., 2009). Therefore, it is of 
paramount importance to precisely understand the nature and causes of mitochondrial 
dysfunctions, and whether they are early or late events in disease evolution.  
In the majority of studies of ALS, the mitochondrial abnormalities were assessed using 
morphological methods, which showed swollen brain and spinal mitochondria with dilated 
cristae, and vacuoles in matrix (Sasaki et al., 2004, Jaarsma et al., 2006). It was suggested that 
vacuolization may depend on accumulation amount, rather than from toxic property, of 
mutant SOD1 (Jaarsma, 2006). Morphologic methods, including quantitative histochemistry, 
and immunological methods, showed that both in ALS patients and tgSOD1 animals, the 
activities of respiratory chain complexes were diminished (Jung et al., 2002), and that the 
spinal cord mitochondria are predisposed to opening of the Ca2+-dependent permeability 
transition pores (mPTP), which trigger death of motor neurons (Martin et al., 2009). There is 
a large body of evidence that spinal cords in tgSOD1 animals are subjected to increased 
oxidative and nitrative stress, as indicated by accumulation of protein carbonyls and 
nitrated proteins (Martin et al., 2007, 2009). These data also demonstrated that mitochondria 
are involved early in the pathogenesis of ALS (Martin et al., 2007, 2009). Recently, Panov et 
al. (2011b) provided direct evidence that isolated mitochondria from the brain and spinal 
cord of tgSOD1 rats generate significantly more reactive oxygen species (ROS) as compared 
with mitochondria from wild type animals. 
Morphological, histochemical and immunological methods provided important information 
about involvement of mitochondria in the pathology, however they do not tell us what 
caused the changes in mitochondrial morphology. Relatively few studies were performed 
on isolated BM and SCM mitochondria from control (Sullivan et al., 2004, Panov et al., 
2011a), tgSOD1 animals (Kirkinezos et al., 2005, Damiano et al., 2006, Fischer et al., 2011, 
Panov et al., 2011b), Wobbler mice (Dave et al., 2003, Xu et al., 2001), or mnd mice, which 
spontaneously develop motor neuron pathology (Bertamini et al., 2002). In their pioneering 
work, Sullivan et al (2004) have shown that normal SCM have lower respiratory activity, 
lower threshold for calcium-induced mitochondrial permeability transition, and a higher 
degree of superoxide radical production (determined with dehydroethidium) and lipid 
peroxidation as compared with BM. However, the dehydroethidium method does not 
identify the origin of superoxide radical. Studies of isolated mitochondria from tgSOD1 mice 
showed that BM and SCM had decreased rates of respiration associated with the loss of 
complex IV activity (Kirkinezos et al., 2005). Very early in the course of the disease, the 
mitochondrial Ca2+ loading capacity was significantly diminished as compared with the 
age-matched control mice (Damiano et al., 2006). Respiratory activities were also diminished 
in SCM of Wobbler mice (Dave et al., 2003, Xu et al., 2001) and mice with motor neuron 
degeneration disease (Bertamini et al., 2002). 
A comparative study of isolated normal and tgSOD1 brain and spinal cord mitochondria 
was published recently by Panov et al. (2011a, b), and the unique metabolic features of BM 
and SCM were described (see also Panov et al, 2009). Normal SCM produced significantly 
more ROS than BM, and this was associated with the succinate-dependent reverse electron 
transport (Panov et al. 2011a). A rather unexpected finding was that BM and SCM isolated 
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from presymptomatic tgSOD1 rats showed almost normal rates of oxidative 
phosphorylation. Panov et all. (2011b) purified mitochondria in a Percoll gradient, and thus 
eliminated damaged mitochondria. This resulted in significantly lower yields of 
mitochondria per 1 gram of tissue of tgSOD1 rats: the yields were diminished by 27% for the 
brain and by 58% for spinal cord as compared with the normal Sprague Dawley rats (Panov 
et al., 2011b). Avossa et al. (2006) used immunocytochemistry and electron microscopy 
techniques to compare wild type and G93A spinal cord tissues after 14 days of growth 
under standard in vitro conditions. Wild type and mutant cultures displayed no differences 
in the analyzed parameters as well as in the number of motor neurons, and there were no 
signs of mitochondria vacuolization or protein aggregate formation in G93A ventral horns. 
Together, the results of Panov et al. (2011b) and Avossa et al. (2006) suggest that in tgSOD1 
rats the BM and SCM are primarily normal but suffer from some pathological events, which 
rapidly deteriorate mitochondria and cause death of neurons. 
In order to better understand the metabolic events involved in putative pathological 
mechanisms of neurodegeneration, we have to discuss the distinctive features of brain and 
spinal cord energy metabolism and their mitochondria. 
3. General features of neuronal energy metabolism 
Neuronal cells are strictly aerobic and require large quantities of ATP produced at high rate 
in order to function normally. Humans brain constitutes only 2% of the body’s weight, but 
accounts for 20% of its resting O2 metabolism (Attwell & Laughlin, 2001). However, even in 
humans, heart and kidney consume significantly more oxygen per unit of the organ’s mass 
than the brain (Rolfe & Brown, 1997). In rats, liver, kidney and heart consume 
correspondingly 2, 3 and 3.9 times more oxygen than the brain (Rolfe & Brown, 1997). Thus 
it is not the necessity for the high rate of oxidative metabolism that is unique for the central 
nerve system, but how the oxidative metabolism is organized in neuronal cells.  
Cortical tissue is composed mainly of two types of cells: the nerve cells (or neurons) and the 
neuroglial cells (or glia). Glial cells greatly outnumber the neurons (Abeles, 1991; Attwell & 
Laughlin, 2001;  Stolzenburg et al., 1989). Glial cells do not directly take part in the interactions 
between neurons, but play an important role in maintaining neuronal metabolism and in 
directing the development and growth of the brain. The classical categorization of neurons 
was based mainly on morphology of the cell body and its dendritic tree, and to a lesser extent 
on the morphology of the axon and its branches (Abeles, 1991).  
There are two main categories of the cortical cells according to their physiological effects on 
each other: excitatory and inhibitory cells. Excitatory cells release transmitters (glutamate) at 
their synaptic ends that, on contact with the postsynaptic membrane, create ion currents that 
depolarize the postsynaptic cell. Inhibitory cells release transmitters, such as Ǆ-aminobutyric 
acid (GABA), that tend to hyperpolarize the postsynaptic cell or to increase the conductance 
of the postsynaptic membrane to chloride, thereby diminishing the effects of the 
depolarizing currents generated by the excitatory synapses. Excitatory synapses dominate 
the brain’s grey matter because excitatory neurons outnumber inhibitory cells by a factor of 
9 to 1, and 90% of synapses release glutamate (Abeles, 1991; Braitenberg & Schüz, 1998). The 
distribution of mitochondria points to these glutamatergic synapses as the major users of 
metabolic energy (Wong-Riley, 1989; Attwell & Laughlin, 2001). 
More than 80% of neuronal mitochondria are located in the dendrites and axonal terminals 
(Wong-Riley, 1989; Attwell & Laughlin, 2001). With high synaptic density of 8 x 108 per 1 
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mm3 in all cortices (the density of synapses is not very much different among species) it is 
clear that in the brain most energy expenditures are associated with synaptic activity, where 
most mitochondria are located (Abeles, 1991). The close spacing of terminals along axons (5 
μm, implying a diffusion time of only 25 milliseconds) make terminal and axonal 
mitochondria functionally indistinguishable (Attwell & Laughlin, 2001).  
Neurons communicate by means of signals that lead to depolarization of their excitable 
membranes. The degree of depolarization of the dendritic or soma membranes is determined 
by complex interactions between excitatory and inhibitory transmitters. The depolarization 
spreads to the axon, leading to release of an excitatory or inhibitory transmitter at the axonal 
endings of the cell, thus allowing information to be transferred to the next cell. When impulses 
are propagated, the cell loses K+ and gains Na+, and in order to preserve excitability the cell 
must extrude Na+ and accumulate K+, using metabolic energy derived from oxidative 
metabolism (Abeles, 1991). Postsynaptic ion fluxes (Na+, K+, Cl-) and presynaptic Ca2+ influx 
consume in grey matter approximately 75% of the brain’s energy (Abeles, 1991; Attwell & 
Laughlin, 2001). Because depolarization and restoration of ionic composition across the 
neuronal membrane occur in the millisecond scale, neuronal mitochondria must provide large 
quantities of ATP in a very short time. This distribution of energy use reflects the fact that a 
chemical synapse is an amplifier: for each glutamate released approximately 100 ions enter the 
postsynaptic terminal (Abeles, 1991). The rest (25%) of the brain’s energy is used for the basic 
“housekeeping” functions, such as maintenance of pH gradients, asymmetrical distributions of 
phospholipids in membrane bilayers, protein synthesis (about 2%), anaplerotic functions and 
recycling of glutamate from synaptic clefts (Attwell & Laughlin, 2001). It was suggested that 
white and grey matter require similar amounts of energy on basic (nonsignaling) cellular 
activities (Attwell & Laughlin, 2001). 
It is widely accepted that nerve tissues of adult mammals use glucose as the major source 
of energy. To fully understand the specifics of energy metabolism in brain, it is important 
to take into account that, in dendrites and synaptic terminals, there is limited space for 
glycolytic enzymes that would provide mitochondria with enough pyruvate derived from 
glucose. Therefore, neurons cannot be functionally and metabolically regarded without 
astroglia. Astrocytes provide neurons with lactate, as the major source of energy, 
replenish the neuronal pool of glutamine and recycle glutamate (Ebert et al., 2003; Pellerin 
et al., 2007; Suzuki et al., 2011). Of the total energy consumed by the brain, approximately 
80% of energy expenditure is satisfied by oxidation of glucose and 20% by oxidation of 
fatty acids (Ebert et al., 2003). As we will see later, neurons also oxidize significant 
amounts of glutamate and GABA as a source of energy. The neurotransmitter GABA is 
formed from glutamate by the action of glutamate decarboxylase. It appears that 
glutamine serves as the precursor for glutamate and GABA. Therefore, the pool of 
glutamine must be constantly replenished in anaplerotic reactions, which occur 
predominantly in astroglia.  
 
 
Fig. 1. Formation of GABA from glutamate.  GAD – glutamate decarboxylase. 
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Because anaplerotic functions of astrocytes require energy, oxidation of fatty acids occurs in 
glial mitochondria (Ebert et al., 2003) providing energy and saving glucose for production of 
lactate in aerobic glycolysis and ǂ-ketoglutarate for synthesis de novo neuromediators glutamate 
and GABA (Waagepetersen et al., 1999; Ebert et al., 2003). Glutamine synthetase is an astrocyte-
specific enzyme (Norenberg & Martinez-Hernandez, 1979), and during octanoate oxidation in 
astrocytes most of the anaplerotic flux in brain is occurring in the TCA cycle associated with 
glutamine production (Ebert et al., 2003). In order to fulfill the task of metabolic provision of 
neuronal functions there are several mechanisms that ensure functional and metabolic 
compartmentalization and complementation between neurons and astroglia, which thus 
exclude competition for energy substrates. Neuronal mitochondria do not possess the full range 
activity of ǃ-oxidation enzymes, whereas glial mitochondria readily oxidize fatty acids (Ebert et 
al., 2003). On the other hand, glial mitochondria do not have active glutamate-aspartate 
translocase (Berkich et al., 2007), which is the key enzyme of the malate aspartate shuttle and the 
major pathway for oxidation of glutamate by neuronal mitochondria. Thus astrocytes do not 
utilize glutamate as a respiratory substrate. The distribution of lactate dehydrogenase isoforms 
between glial cells and neurons promotes aerobic glycolysis in astroglia and utilization of 
lactate by neurons as the major respiratory substrate (Pellerin et al., 2007).  
4. In activated neurons mitochondria utilize a mixture of substrates 
Mitochondria are devices for burning hydrogen producing water and releasing energy, a 
large part of which is accumulated as electrochemical transmembrane potential (ΔμH+) 
(Mitchell, 1977; Nicholls, 2008). ΔμH+ is utilized for production of ATP, and other useful 
work in the mitochondria and cell. Therefore lactate, which has additional hydrogen, as 
compared with pyruvate, has higher energetic value for neuronal mitochondria. In the 
cytosol of a neuron, lactate is oxidized to pyruvate in the reaction catalyzed by lactate 
dehydrogenase (LDH): NAD+ + Lactate  NADH + H+ + Pyruvate. Pyruvate is transported 
into mitochondria and metabolized. 
 
 
Abbreviations: AST – aspartate aminotransferase; GAT – glutamate-aspartate transporter, MDH – 
malate dehydrogenase; MKgT – malate- ǂ -ketoglutarate transporter; OAA – oxaloacetate 
Fig. 2. The malate aspartate shuttle. In a cell with respiring energized mitochondria the 
malate aspartate shuttle serves for transport and oxidation of hydrogen from cytosolic 
NADH to mitochondrial respiratory chain. The process is unidirectional because GAT is 
electrogenic and the matrix NADH is rapidly oxidized by respiratory chain.  
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In order to rapidly oxidize lactate to pyruvate, the cytosolic NADH must be oxidized back 
to NAD+. In neurons the task of reoxidation of the cytosolic NADH and transport of 
hydrogen into mitochondria occur via a number of functionally coupled cytosolic and 
mitochondrial enzymes, which form the malate-aspartate shuttle (MAS) (Figure 2). 
Glutamate is a necessary component of MAS. Because nonsynaptic and presynaptic 
neuronal mitochondria effectively oxidize glutamate (Yudkoff et al. 1994), neuronal cells 
constantly have to replenish the cytosolic pool of glutamate. 
Until recently, it was generally accepted that most of the glutamate is rapidly removed 
from the synaptic cleft by glutamate transporters EAAT1 (GLT-1) and EAAT2 (GLAST) 
located on presynaptic termini and glial cells (Furness  et al., 2008). However, recent data 
show that a significant fraction of glutamate is rapidly bound and transported by the 
glutamate transporter isoform, EAAT4, located juxtasynaptically in the membranes of 
spines and dendrites (Auger & Attwell., 2000; Brasnjo& Otis., 2004). EAAT4 protein was 
found to be omnipresent throughout the fore- and midbrain (Massie et al., 2008). These 
data suggest that postsynaptic transport of glutamate into nerve terminals, where 
mitochondria are located (Abeles, 1991), may occur in all brain regions. According to 
calculations of Brasnjo and Otis (2004), in a single synapse EAAT4 bind and transport 
postsynaptically about 1.3 ± 0.1 x 106 glutamate molecules. In the brain, on average, 1 mm3 
of tissue contains 1 x 108 synapses (Abeles, 1991; Nicholls, 1993). Because of the high 
density of synaptic contacts, the neuronal cells may be exposed to mediators released 
from hundreds of firing synapses. Thus in a narrow space of spines and dendrites several 
million glutamate molecules postsynaptically transported from synaptic boutons may 
create local cytosolic concentration of glutamate in a low mM range. Consequently, 
neuronal mitochondria, particularly those located at the axonal or dendritic synaptic 
junctions may temporarily metabolize, in addition to pyruvate, some amounts of 
glutamate (Yudkoff et al. 1994;  Panov et al. 2009). Besides, GABA is also transported 
postsynaptically where it is catabolized in mitochondria to succinate (Tillakaratne et al., 
1995).  
As we have mentioned, for rapid conversion of lactate to pyruvate, postsynaptic neurons 
must receive a certain amount of glutamate to fuel MAS to recycle cytosolic NAD+ 
(Berkich et al., 2007). Importantly, the activity of the brain mitochondrial isoform of 
aspartate glutamate transporter  is controlled by Ca2+ (Pardo et al., 2006). Therefore 
increased neuronal activity through small changes in the extramitochondrial Ca2+ 
activates MAS, whereas increased mitochondrial Ca2+ activates mitochondrial respiration 
(Nicholls, 2009). 
There is evidence (Yudkoff et al., 1994), that in the presence of glutamate + pyruvate, the 
tricarboxylic acid (TCA) cycle in brain mitochondria operates as two coupled cycles: one 
(cycle A) leads from ǂ-KG to OAA, and another (cycle B) from OAA to a-KG that includes 
the citrate synthase reaction (see figure 3). According to Yudkoff et al. (1994), the flux of 
substrates through cycle A is 3-5-fold faster than that through the cycle B. Thus, with 
pyruvate + glutamate + malate, activation of ǂ-ketoglutarate dehydrogenase complex (ǂ-
KGDHC) and succinate dehydrogenase (SDH) may significantly increase the rates of the 
tricarboxylic acid cycle  (TCA) cycle and respiratory chain in state 3 and state 3U (Fig. 3). A 
high turnover of cycle A with activated SDH would increase reverse electron transport 
(RET) and the associated ROS production. 
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Abbreviations: ALT – alanine aminotransferase; AST –aspartate aminotransferase; SDH – succinate 
dehydrogenase (Complex II). 
Fig. 3. The tricarboxylic acid cycle in the presence of pyruvate and glutamate operates as 
two coupled cycles A and B. In the presence of glutamate and/or pyruvate as substrates 
high activities of AST and ALT may “short-circuit” oxaloacetate and ǂ-ketoglutarate, thus 
converting the “normal” TCA cycle into two independently operating cycles A and B. 
Malonate is a quasi-irreversible inhibitor of SDH, whereas oxaloacetate (OAA) is a 
competitive but strong inhibitor. SDH has similar affinities for succinate and malate, but 
oxidation of malate results in formation of OAA on the enzyme’s active center, which makes 
malate a strong inhibitor of SDH. 
Thus in activated neurons mitochondria may oxidize simultaneously glutamate, pyruvate, 
and metabolites of the TCA cycle, such as malate, and succinate. Postsynaptically 
transported GABA is catabolized in mitochondria to succinate (Tillakaratne et al., 1995). 
Under these conditions, brain (BM) and spinal cord (SCM) mitochondria significantly 
increase the rate of oxidative phosphorylation and the succinate-dependent production of 
ROS (Panov et al., 2009, 2011a).  With glutamate + pyruvate + malate as substrates, 
increased production of ATP and ROS was associated with dramatic increase in the matrix 
concentration of ǂ-ketoglutarate (Balasz, 1965a) due to increased activities of mitochondrial 
aminotransferases AST and ALT (Fig. 3).  Under these conditions glutamate dehydrogenase 
(GLDH) does not participate in production of ǂ-KG (Balasz, 1965b). Since AST and ALT are 
present in great excess, compared with the respiration rate, the oxaloacetate (OAA) formed 
is continuously removed by the transamination reactions. Balazs (1965b) concluded that a 
competition takes place between the ǂ-KGDHC and GLDH, probably for NAD+, resulting 
in preferential oxidation of ǂ-oxoglutarate.  
5. Distinctive properties of ROS generation in brain and spinal cord 
mitochondria 
In neuronal tissue mitochondria are the major source of ROS production (Stowe & 
Camara, 2009), which is indispensable feature of aerobic metabolism. It is generally 
accepted that during oxidation of the NAD-dependent substrates the limiting step is at 
the NADH-dehydrogenase site of Complex I (see Panov et al. 2007, 2009).  With succinate 
as a substrate, production of ROS is significantly higher, because Complex II, which is 
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also part of the TCA cycle – succinate dehydrogenase (SDH), feeds electrons into the 
mitochondrial pool of  CoQ10 (ubiquinone, Q). The reduced ubiquinone (QH2) in its turn 
reduces the sites on Complex I that can generate superoxide radicals at high rate. This 
process, known as reverse electron transport, is energy-dependent and inhibited by 
rotenone. Some researchers deny the significance of succinate in ROS production on the 
pretext that succinate concentration is too low in mitochondria (Starkov, 2008; Stowe & 
Camara, 2009; Zoccarato et al., 2007). As we have shown recently, however,  brain and 
spinal cord mitochondria  may produce succinate even in the presence of pyruvate + 
malate (Panov et al., 2009) , and as we show in this article (see Fig. 6) even with glutamate 
+ malate a large part of ROS production may be associated with oxidation of succinate. 
However a particularly large production of the succinate-dependent ROS was observed in 
the presence of glutamate + pyruvate + malate (Panov et al., 2009, 2011a, 2011b). With 
these substrates the increased succinate oxidation was caused by a dramatic increase in 
mitochondrial ǂ-ketoglutarate due to high activities of aminotransferases (Balasz, 1965a, 
1965b). Besides, GABA is catabolized with formation of succinate in postsynaptic 
mitochondria (Tillakaratne et al. 1995). Thus, in the excited neurons succinate is an 
indispensable mitochondrial metabolite. In this paper we provide evidence that ROS 
generation associated with the succinate-dependent reverse electron transport is a subject 
for phenotypic variations. 
Another objection to the importance of reverse electron transport (RET) in ROS generation 
argues that, because RET is energy-dependent, in the functioning cell the diminished 
mitochondrial energization will inhibit production of ROS (Starkov, 2008). The latter 
objection is valid for the most perpetually functioning organs, such as heart, kidney and 
liver. But it is only partially applicable to brain and spinal cord where a very large number 
of mitochondria are located at axonal and dendritic junctions (Wong-Riley, 1989). At the 
narrow spaces of synaptic junctions there is no other task for mitochondria beside provision 
of ATP for restoration of ionic composition in excited synapses. If the neurons are not 
excited, mitochondria become fully energized and produce ROS at high rate. Therefore 
axonal and synaptic junctions, including neuro muscular junctions, are particularly 
vulnerable to oxidative damage if neurons are not excited for some reason. 
Another possible reason why the succinate-dependent ROS production was underrated 
could be the fact that most researchers use “classical” mixtures of substrates,  such as 
glutamate + malate, pyruvate + malate, succinate alone, or, very often, in the presence of 
rotenone.  
Figure 4 shows a representative experiment with the BM and SCM isolated in 2007 from 
tg SOD1 rats.  One can see that with glutamate + malate, the rate of ROS production, 
measured as H2O2, there were no differences between tgBM and tgSCM, wtBM or wtSCM 
(not shown). With pyruvate + malate as substrates, tgSCM generated significantly more 
ROS than tgBM (see Fig. 5). This was because SCM in general oxidize succinate at higher 
rate than BM, presumably due to the lower intrinsic inhibition of SDH by oxaloacetate 
(Panov et al., 2011a).  However, when tgBM and tgSCM oxidized a mixture of glutamate + 
pyruvate + malate, there was a several-fold increase in ROS production. TgSCM produced 
much more ROS than tgBM (Fig. 4, see also Fig. 6 in Panov et al., 2011b). Thus the usage 
of physiologically relevant mixtures of substrates is far more informative for 








Fig. 4. Production of ROS by brain and spinal cord mitochondria from tgSOD1 rats. 
Mitochondrial production of ROS was registered as H2O2  by Amplex  red method (Panov et 
al., 2009). 
We suggested the following metabolic scenario for the neuronal mitochondria located at 
synaptic junctions. During neuronal activity, the postsynaptic mitochondria are exposed to 
increased levels of pyruvate and glutamate, which enhance ATP production due to specific 
interactions between the glutamate transforming enzymes and the TCA cycle enzymes. This 
effect of the substrate mixtures is specific for the BM, and SCM (Panov et al., 2009, 2011a). 
As soon as activation of a synapse comes to an end, transport of glutamate from the synaptic 
cleft would also stop. As a result, activation of respiration induced by the simultaneous 
presence of glutamate and pyruvate will also end because glutamate becomes exhausted. 
Thus the neuromediator glutamate controls energy metabolism in brain not only at the level 
of astrocytes by enhancing production of lactate, but also at the level of neurons by 
controlling the activity of MAS and specific interactions between aminotransferases. 
In the absence of neuronal activation, SDH (Complex II) in the postsynaptic mitochondria is 
inhibited by OAA (Panov et al. 2010a). The physiological significance of this inhibition is to 
prevent excessive ROS production associated with reverse electron transport. This is 
particularly  important for neurons because with pyruvate, which is the major 
mitochondrial substrate in resting neurons (Pellerin et al., 1994; Hertz, 2004), there is a 
substantial production of succinate and thus a possibility of increased RET-dependent ROS 
production (see Fig. 5A, 5B; Panov et al. 2009, 2011a, 2011b). During increased neuronal 
activity glutamate and pyruvate temporarily release the inhibition of SDH. Increased ATP 
production (state 3) prevents generation of ROS (Starkov, 2008; Votyakova & Reynolds, 
2001). Because SCM in general oxidize succinate at higher rates than BM, due to lower 
intrinsic inhibition of SDH,  they are more vulnerable to oxidative stress than BM (Panov et 
al., 2011a, 2011b).  
Activation of oxidative phosphorylation and increased ROS generation with pyruvate + 
glutamate + malate was observed only with BM and SCM  (Panov et al., 2009, 2011a). 
However, activation of succinate oxidation by pyruvate and glutamate may be a common 
phenomenon for mitochondria from many organs. Our experiments with mitochondria 
from different organs and different species of rats and mice, and with one species (Sprague 
Dawley) of rats over period of 6 years, have shown that mitochondrial metabolism is a 
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subject to phenotypic variations between species and in one species with time (Panov et al., 
2010). Below we describe how changes in mitochondrial metabolism of BM and SCM of wild 
type Sprague Dawley rats affected mitochondrial dysfunctions in tgSOD1 rats in 2007 and 
2010. 
6. Differences between BM and SCM isolated in 2007 and 2010 in the rates of 
ROS production with different substrates 
ROS production by mitochondria strongly depends on the metabolic state of the 
mitochondria, type of substrates, and is also tissue-specific (Kwong, Sohal, 1998; Muller et 
al., 2008, Panov et al., 2007). There are two types of ROS production by mitochondria – 
energy-dependent and non-energy-dependent (Panov et al., 2007). The energy-dependent 
ROS production is associated with the reverse electron transport (Kwong, Sohal, 1998; 
Muller et al., 2008, Panov et al., 2007). ROS production, which does not depend on 
energization and the metabolic state of the mitochondria may occur on complexes I, II and 
III and depends on the presence of inhibitors of the electron transport (Kwong, Sohal, 1998; 
Panov et al., 2007; St-Pierre et al. 2002). In the absence of respiratory inhibitors the rate of the 
non-energy dependent ROS production is relatively slow (Panov et al., 2007). We have 
shown that in BM and SCM the major source of ROS correlates with the reverse electron 
transport, which occurs during oxidation of succinate (Kwong, Sohal, 1998; Panov et al., 
2007, 2009, 2011a, b), fatty acids (Panov et al., 2010c), or ǂ-glycerophosphate (Tretter et al., 
2007). Thus respiration rates in State 4 in the well coupled mitochondria oxidizing succinate 
correlates with the rates of ROS production (Panov et al., 2007, 2011a). Therefore changes in 
the rates of ROS production presented in Figure 4 closely reflect metabolic pattern of the 
mitochondria. Another reason why we do not present respiratory data is that in 2010 we 
had limited number of tgSOD1 rats, which precluded obtaining statistically significant data 
with all substrates and their mixtures. 
In our studies on mitochondrial dysfunctions in the rat model of ALS (tgSOD1), we used as 
a reference control Sprague Dawley rats from Taconic (Germantown, NY). In the years of 
2005-2007 we have discovered, that in this strain both BM and SCM had a unique metabolic 
attribute, which was absent in mitochondria from other organs: during simultaneous 
oxidation of pyruvate + glutamate + malate the rates of oxidative phosphorylation and the 
State 4 ROS production were significantly higher than with either glutamate or pyruvate 
alone (Panov 2009, 2011a). This substrate mixture corresponded to the metabolic situation in 
activated neurons (Panov et al., 2009). Addition of malonate, a potent inhibitor of SDH, 
attenuated the rates of respiration and ROS production with pyruvate + malate and 
glutamate + pyruvate + malate to the level with glutamate + malate.  
With succinate as a substrate, ROS production was several times higher than with glutamate 
+ pyruvate + malate, and was further increased in the presence of glutamate + pyruvate 
(Fig. 5A, 5B). The stimulation of the succinate-supported State 4 respiration and ROS 
production by glutamate and pyruvate was attributed to removal of endogenous 
oxaloacetate, which inhibits succinate dehydrogenase (SDH) (Panov et al. 2009, 2010). SCM 
from the control rats produced significantly more ROS than BM, particularly with the 
succinate containing substrate mixtures (Figure 5A, 5B; see also Panov et al. 2009, 2011a). We 
have concluded that in BM the activity of SDH was primordially inhibited by endogenous 
oxaloacetate (Panov 2009, 2010). This intrinsic inhibition of SDH by oxaloacetate was less 
evident in SCM, and therefore SCM produced more ROS with substrate mixtures that 
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produced or contained succinate (Panov 2011a). The described above metabolic features of 
BM and SCM were consistently observed in the wild type and tgSOD1 rats during period of 
2005 – 2007 years (Panov et al. 2009, 2011a, 2011b). 
 
  
A. Brain mitochondria; B. Spinal cord mitochondria. Dark grey – wild type rats in 2007, light gray – 
wild type rats in 2010. Mitochondria were incubated in a medium containing: 125 mM KCl, 10 mM 
MOPS, pH 7.2, 2 mM MgCl2, 2 mM KH2PO4, 10 mM NaCl, 1 mM EGTA, 0.7 mM CaCl2. At a Ca2+/EGTA 
ratio of 0.7, the free [Ca2+] is close to 1 M as determined using Fura-2. The substrate concentrations 
were: 5 mM succinate without rotenone, 5 mM glutamate, 2.5 mM pyruvate, and 2 mM malate. (Panov 
et al. 2009, 2011a, b). The results are presented as Mean ± SE, n = 3, and show the rates of ROS 
production in pmol H2O2 /minute/mg mitochondrial protein. Additions: 5 μM Amplex red, 1 U of 
horse radish peroxidase, 50 U of superoxide dismutase (Sigma), 0.05 mg mitochondria, glutamate 5 mM 
+ malate 2 mM (G + M); pyruvate 2.5 mM + malate 2 mM (P + M); glutamate 5 mM + pyruvate 2.5 mM 
+ malate 2 mM (G + P + M); succinate 5 mM (S); succinate 5 mM + glutamate 5 mM + pyruvate 2.5 mM 
+ malate 2 mM (S + G + P + M). Statistics: ** p < 0.01; *** p < 0.001. For each year the data were 
compared with the rates of ROS production with glutamate + malate. 
Fig. 5. Comparison of ROS production by wild type brain and spinal cord mitochondria, 
isolated in 2007 and 2010, oxidizing different substrates and substrate mixtures. 
In 2008 we observed that BM and SCM from the wild type rats displayed a metabolic 
pattern that was different from the one described above. To highlight the differences in 
metabolic features of BM and SCM, we present data restricted to 2007, when significant 
mitochondrial dysfunctions in tgBM and tgSCM were observed as described in (Panov et al. 
2011b), and 2010, when the tgSOD1 rat line failed to develop the disease features, and 
mitochondria showed little or no dysfunction as compared with the corresponding wild 
type animals. The related metabolic properties of the BM and SCM isolated from wild type 
animals in 2007 are presented and compared with those of 2010 in figures 5A and 5B.  
Figure 5A compares ROS production by WT-BM isolated in 2007 and 2010. Of notice, the rate 
of ROS production by WT-BM isolated in 2010 was 3.5 fold higher than WT-BM isolated in 
2007. However, in 2010 there was no differences in State 4 respiration (not shown) and ROS 
production (Fig. 5A) when BM oxidized glutamate + malate, pyruvate + malate or glutamate + 
pyruvate + malate. In contrast to WT-BM isolated in 2007, the much higher basic rate of ROS 
production supported by glutamate + malate in 2010 was inhibited by malonate to the level 
close to that in 2007 (Fig. 6). Similarly, in 2010 malonate inhibited ROS production in BM 
oxidizing glutamate + pyruvate + malate (Fig. 6) and pyruvate (not shown).  
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In contrast to WT-BM isolated in 2007, the WT-BM isolated in 2010 produced ROS 
supported by succinate at much lower rates than with glutamate + pyruvate + malate (Fig. 
5A). Addition of glutamate + pyruvate + malate to the WT-BM -2010 oxidizing succinate 
stimulated ROS production only to the level with glutamate + malate (Fig. 5A). Similar 
metabolic features were also observed with the WT-SCM isolated in 2010, although the 
differences from 2007 WT-SCM were smaller than for the BM (Fig 5B). It is important to note 
that in 2010 WT-SCM generated ROS with different substrates at the same levels as WT-BM, 
whereas in 2007 the WT-SCM generated significantly more ROS than the corresponding 
WT-BM (Fig. 5A and 5B. Note the scale difference between the figures). 
 
 
Incubation conditions and designations as described in Fig. 5. Malonate 5 mM was added before 
mitochondria. Dark gray – BM isolated in 2007, light gray columns – BM isolated in 2010. Statistics: *** p 
< 0.001, NS – not significant difference. The dark columns and grey columns were compared with the 
corresponding column representing ROS production with glutamate and malate, taken as 100%.  
Fig. 6. Effect of malonate on ROS production by wild type brain mitochondria, isolated in 
2007 and 2010, oxidizing glutamate + malate, pyruvate + malate, and glutamate + pyruvate 
+ malate. 
The sensitivity of the State 4 ROS production supported by either pyruvate or glutamate to 
malonate (Fig, 6; Panov et al. 2009) demonstrates that at least with BM and SCM both 
glutamate and pyruvate cannot be regarded as “pure complex I substrates”, as is commonly 
accepted. In BM and SCM during oxidation of glutamate or pyruvate, and particularly when 
glutamate and pyruvate are present simultaneously, significant amounts of ǂ-ketoglutarate 
can be formed in transaminase reactions, which is further converted to succinate (Balasz, 
1965; Panov et al. 2009). 
7. Effects of metabolic phenotype on ROS production by tgBM and tgSCM 
Figure 7A shows generation of ROS by tgBM and tgSCM isolated from tgSOD1 rats in 2007, 
and figure 7B presents corresponding results for tgBM and tgSCM isolated from tgSOD1 
rats in 2010. The figures clearly show that in spite of higher basic ROS production with 
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glutamate and pyruvate by BM and SCM in 2010 (Fig. 5A and 5B), the overall rates of ROS 
generation with physiologically relevant substrate mixture - glutamate + pyruvate + malate 
were 5 times lower for tgBM and 10 times for tgSCM , when compared with transgenic 
mitochondria in 2007 (Fig. 7A and 7B). 
 
  
A. 2007; B. 2010. Dark grey – brain mitochondria, light gray – spinal cord mitochondria. Incubation 
conditions as in Fig. 5. Statistics: * p < 0.05; ** p < 0.01; *** p < 0.001. The data for tgSCM were compared 
with the corresponding results for tgBM. 
Fig. 7. Generation of ROS by brain and spinal cord mitochondria from tgSOD1 rats, 
isolated in 2007 and 2010, oxidizing various substrates. 
Similar multiple-fold differences in ROS production existed also with succinate and 
succinate containing substrate mixtures (Figs. 7A, 7B). In tgBM and tgSCM, the increases in 
ROS generation were substrate specific and depended on activity of SDH. These results led 
us to conclusion that changes in the metabolic phenotype of neuronal mitochondria, which 
occurred in 2008, resulted in a dramatic decrease in production of ROS in tgSOD1 rats.  
8. Hydrogen peroxide is the major species to cause oxidative stress in 
tgSOD1 mitochondria 
One of the distinctions of BM and SCM is a very high activity of MnSOD (SOD2) (Panov et 
al., 2009, 2011a, 2011b), which is distinct from the heart and skeletal muscle mitochondria 
(Muller et al., 2008). Even at very high rates of ROS production, such as shown in Figures 4 
and 5A, 5B, addition of external SOD did not increase fluorescence of resorufin. The high 
activity of SOD2 means that BM and SCM effectively eliminate superoxide radicals from the 
matrix by converting them to H2O2. Therefore, we suggest that the major damaging factor in 
tgSOD1 motor neurons is H2O2. It was shown that H2O2 can interact with Cu,Zn-SOD 
(SOD1) resulting in peroxidase activity of SOD1 (Liochev, Fridovich, 2004), formation of 
strong oxidant CO3
 radical (reviewed in Valentine et al., 2005), enzyme inactivation, release 
of Cu2+, protein oxidation and aggregation (Ramirez et al., 2009, Durer et al., 2009). At this 
point, the damaging effects of H2O2 will be increased dramatically because Cu2+ ions are 
several orders more active than Fe2+ in Fenton-like reaction with H2O2 (Dikalov et al., 2004), 
which will produce hydroxyl radical-like species and further drive lipid peroxidation, 
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protein damage and promote mitochondrial dysfunction. Loss of metals by mutant SOD1 
leads to formation of amyloid-like aggregates (Durer et al., 2009). Mutations in SOD1 
amplify reactions with H2O2, increase the lifetime of incorrectly folded states, and if exposed 
to even mild oxidative stress, incorrect disulfide links form and stabilize larger aggregates 
that may be resistant to the degradation by the quality control machinery of the cell, and 
thus increase association with mitochondria (Field et al., 2003; Furukawa, O’Halloran, 2008). 
9. Proposed mechanisms of increased ROS production in tgSOD1 
mitochondria  
There is strong evidence that tgSOD1 selectively binds to the outer (Vande Velde et al., 2008) 
and inner mitochondrial membranes (Liu et al., 2004; Ahtoniemi et al., 2008). Mutant SOD1 
protein associated with mitochondria forms cross-linked oligomers and causes a shift in the 
redox state of respiratory components (Ferri et al., 2006). We propose a mechanism by which 
tgSOD1 might increase generation of ROS associated with reverse electron transport. The 
hypothesis is based on our recently published data on the effects of cholesterol ǃ-D-
glucoside and cycad phytosterol glucosides on ROS generation by BM (Panov et al., 2010b). 
These compounds are neurotoxic and suspected as the cause of the cluster of 
neurodegenerative disorders in the western Pacific termed amyotrophic lateral sclerosis–
parkinsonism dementia complex (ALS-PDC) (Wilson et al., 2002). When added in vitro to 
mitochondria, cholesterol ǃ-D-glucoside increased ROS production, which was specifically 
dependent on activity of SDH. Cholesterol ǃ-D-glucoside is known to diminish the surface 
area of the membranes and thus affect the activity of the membrane’s enzymes 
(Deliconstantinos et al., 1989). Here we suggest, that tgSOD1 upon its interaction with the 
mitochondria may change physical-chemical properties of the membranes and increase the 
rate of reverse electron transport in a way similar to that of cholesterol ǃ-D-glucoside.   
10. Oxidative stress increases sensitivity of mitochondria to Ca2+-dependent 
excitotoxicity 
Increased oxidative stress makes mitochondria more sensitive to the Ca2+-induced 
permeability transition, which may initiate apoptotic or necrotic cell death (Halestrap et al., 
2000; Nicholls, 2008b, 2009). Mitochondria from tgSOD1 animals have high sensitivity to the 
deleterious effects of calcium (Martin et al., 2009). SCM are particularly sensitive to calcium 
overload (Sullivan et al., 2004, Panov et al., 2011a). This scenario becomes very likely to 
occur in tgSOD1 animals in view of the fact that spinal cord tissue contains 8 times more 
calcium than brain tissue (Panov et al., 2011a). We estimated that when normalized for 1 
gram of tissue, BM could sequester several times more Ca2+ than was available in the whole 
tissue. SCM, on the other hand, could sequester only approximately 20% of the total spinal 
cord tissue Ca2+ (Panov et al., 2011a). We suggest that the high content of Ca2+ is necessary 
to hold together the sheets of myelin, which protects the neurons. We have shown recently 
that increased oxidative stress promotes demyelination in brains of OXYS rats with 
genetically accelerated aging, which was ameliorated by feeding of animals with malate 
(Kolosova et al. 2011). Underwood et al. (2010), using magnetic resonance imaging, have 
shown signs of demyelination in the lumbar spinal cord of ALS-affected SOD1 mice, which 
were limited to white matter tracts arising from the motor neurons, whereas sensory white 
matter fibers were preserved. Damages to myelin sheets of motor neurons may evidently 
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release large amounts of calcium. The tissue calcium content in the spinal cord from 
presymptomatic tgSOD1 rats was diminished by 26% (Panov et al., 2011b). Thus, oxidatively 
damaged mitochondria may encounter increased amounts of Ca2+ released during 
demyelination and undergo permeability transition. Halestrap (2005) has pointed out that 
when mitochondria massively undergo permeability transition, the cells will die by necrosis, 
which was documented Martin et al.(2009) for ALS animals. 
11. Conclusions 
The results presented by us in this and other papers (Panov et al., 2009, 20011a, 2011b) lead 
us to suggest the role of the brain and spinal cord mitochondria in the loss of motor neurons 
in ALS. We hypothesize that increased oxidative stress associated with specific metabolic 
phenotypes, which promote reverse electron transport due to reduction of the membrane 
pool of ubiquinone by succinate (Panov et al., 2009, 2011a, 2011b) or fatty acids (Panov et al.,  
2010c), is a prerequisite for cases of sporadic ALS. The energy-dependent reverse electron 
transport is a way of dissipation of the mitochondrial membrane potential, which increases 
the rate of resting mitochondrial respiration.  In mammals, the standard metabolic rate 
depends on the intrinsic (in state 4) mitochondrial proton conductivity (Rolfe & Brown , 
1997). Therefore in patients with ALS hypermetabolism could be associated with the 
systemically increased dissipation of mitochondrial membrane potential. The specific 
vulnerability of motor neurons in ALS is, more likely than not, associated with the specific 
features of spinal cord described in Panov et al. (2011a, 2011b).  
Normally, SCM produce significantly more ROS than BM when oxidizing physiologically 
relevant mixture of neuromediator glutamate and the tricarboxylic acid cycle substrates 
pyruvate, succinate and malate. Mutated SOD1 is extremely sensitive to the damaging effect 
of H2O2, which in tgBM and tgSCM were dramatically increased. This results in 
demetallation of mSOD1 and association with mitochondria, thus changing the physical 
properties of the mitochondrial membranes and further enhancing production of ROS. 
Increased oxidative stress initiates damage to myelin and released the tissue calcium. 
Finally, oxidatively damaged mitochondria undergo the Ca2+-induced permeability 
transition, and motor neurons die by apoptotic or necrotic pathway. Thus, mitochondria are 
early and directly involved in the pathogenesis of ALS. We suggest that sporadic ALS is 
preferentially acquired by individuals with the mitochondrial metabolic phenotype, that 
promotes very high levels of ROS production. In individuals with mutated SOD1 gene, the 
abnormal SOD1 protein has high sensitivity to deleterious effect of H2O2 and the disease 
may develop even at normal levels of ROS production. 
12. Proposals for future studies 
The results and the hypothesis presented in this article highlight the importance to consider 
determination of metabolic phenotypes together with the disease mechanisms when 
working with patients or animal models of the ALS.  
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